RANDOMIZED COMPARATIVE TRIAL OF INTERFERON-ALPHA VERSUS PLACEBO IN HEPATITIS-B VACCINE NONRESPONDERS AND HYPORESPONDERS

被引:24
作者
GOLDWATER, PN
机构
[1] Microbiology Department, The Adelaide Children's Hospital (Women's and Children's Hospital), North Adelaide
关键词
HEPATITIS B VACCINE; NONRESPONSE; INTERFERON;
D O I
10.1016/0264-410X(94)90116-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Adults who had received 4 x 20 mu g doses of hepatitis B (Engerix-B) vaccine (appropriately administered) and who had failed to develop detectable anti-HBs or who had had a minimal response (<10 IU l(-1)) were randomized to receive either a fifth dose of Engerix-B (20 mu g) plus 1 million units of interferon-alpha or a fifth dose of vaccine plus saline placebo intramuscularly (deltoid). Both vaccine and test material were given together in one syringe and participants were blind as to the syringe contents. Anti-HBs was tested (by enzyme immunoassay) one to three months following the injection. Anti-HBs results from the 150 non-responders (NR) and the 26 hyporesponders (HR) are reported. Of NRs receiving a fifth dose plus placebo, 41% developed anti-HBs, whilst 53% of those receiving interferon-alpha developed anti-HBs. The response rates did not differ significantly. Of HRs receiving vaccine plus placebo, 70% showed an increase in their anti-HBs titre, while 87.5% of those receiving interferon-alpha with vaccine had titre rises. Vaccinee groups were well matched for age, sex and body mass index and the interval between injection and venepuncture. Side-effects from interferon-alpha were of short duration and were tolerated by vaccinees seeking protection from hepatitis B infection. On the basis of this study, a fifth dose of vaccine in non- and hyporesponsive vaccinees is recommended. Interferon-alpha was of unproven value but it may increase the likelihood of seroconversion in NRs and its use could be considered in subjects at continued high risk of contracting hepatitis B. Anti-HBs responses were measurably higher in interferon-alpha recipients than in placebo recipients.
引用
收藏
页码:410 / 414
页数:5
相关论文
共 19 条
  • [1] GENETIC PREDICTION OF NONRESPONSE TO HEPATITIS-B VACCINE
    ALPER, CA
    KRUSKALL, MS
    MARCUSBAGLEY, D
    CRAVEN, DE
    KATZ, AJ
    BRINK, SJ
    DIENSTAG, JL
    AWDEH, Z
    YUNIS, EJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (11) : 708 - 712
  • [2] IMPROVEMENT OF HEPATITIS-B VACCINE BY THE USE OF A NEW ADJUVANT
    BYARS, NE
    NAKANO, G
    WELCH, M
    LEHMAN, D
    ALLISON, AC
    [J]. VACCINE, 1991, 9 (05) : 309 - 318
  • [3] NONRESPONSIVENESS TO HEPATITIS-B VACCINE IN HEALTH-CARE WORKERS - RESULTS OF REVACCINATION AND GENETIC TYPINGS
    CRAVEN, DE
    AWDEH, ZL
    KUNCHES, LM
    YUNIS, EJ
    DIENSTAG, JL
    WERNER, BG
    POLK, BF
    SNYDMAN, DR
    PLATT, R
    CRUMPACKER, CS
    GRADY, GF
    ALPER, CA
    [J]. ANNALS OF INTERNAL MEDICINE, 1986, 105 (03) : 356 - 360
  • [4] DEMAEYER E, 1981, BIOL INTERFERON SYST, P203
  • [5] THE CELLULAR BASIS FOR LACK OF ANTIBODY-RESPONSE TO HEPATITIS-B VACCINE IN HUMANS
    EGEA, E
    IGLESIAS, A
    SALAZAR, M
    MORIMOTO, C
    KRUSKALL, MS
    AWDEH, Z
    SCHLOSSMAN, SF
    ALPER, CA
    YUNIS, EJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (03) : 531 - 538
  • [6] INTERFERON AS AN ADJUVANT FOR HEPATITIS-B VACCINATION IN NON-RESPONDER AND LOW-RESPONDER POPULATIONS
    GROB, PJ
    JOLLERJEMELKA, HI
    BINSWANGER, U
    ZARUBA, K
    DESCOEUDRES, C
    FERNEX, M
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1984, 3 (03) : 195 - 198
  • [7] HOLLINGER FB, 1989, AM J MED, V87, pS36
  • [8] DURATION OF IMMUNITY AFTER HEPATITIS-B VACCINATION - EFFICACY OF LOW-DOSE BOOSTER VACCINE
    HOROWITZ, MM
    ERSHLER, WB
    MCKINNEY, WP
    BATTIOLA, RJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 108 (02) : 185 - 189
  • [9] HEPATITIS-B INFECTION IN THE UNITED-STATES - RECENT TRENDS AND FUTURE STRATEGIES FOR CONTROL
    KANE, MA
    ALTER, MJ
    HADLER, SC
    MARGOLIS, HS
    [J]. AMERICAN JOURNAL OF MEDICINE, 1989, 87 (3A) : S11 - S13
  • [10] KURIYAMA S, 1988, CLIN EXP IMMUNOL, V72, P383